• About us
• Contact

Advertisement

Organisation › Details

Etherna Immunotherapies N.V.

eTheRNA immunotherapies NV is developing immunotherapy and vaccine products for the treatment of cancer and infectious disease from its mRNA chemistry, antigen identification, lipid chemistry and delivery and process engineering platforms. The company is headquartered in Belgium and was established in 2013. Its founding shareholders include Progress Pharma and VUB. eTheRNA is supported by an international group of specialised investors; BNP Fortis Private Equity, Boehringer Ingelheim Venture Funds, Everjoy Fortune PTE. LTD, Grand Decade Development Limited, Fund+, LSP, Novalis Lifesciences, Omega Funds, PMV and Ying Zhou Enterprise Management Company Limited who share the Company’s ambition to build a world-leading company in the RNA field. To date, the Company has raised €63 million of venture funding. *

 

	Start	2020-06-16 renamed before
	End	2023-10-17 renamed
	Group	Etherna (Group)
	Today	Etherna N.V.
	Predecessor	Etherna BVBA
	Successor	Etherna N.V.
	Industry	mRNA technology
	Industry 2	lipid nanoparticle technology (LNP technology)
	Person	Powell, Steven (eTheRNA CEO 202006 before Macrophage Pharma 201705 CEO)
	Person 2	Dekkers, Marijn E. (Novalis LifeSciences 202208 Chairman + Founder before Bayer CEO + Thermo Fisher CEO)
	Region	Belgium_oo
	Country	Belgium
	Street	10 Galileilaan
	City	2845 Niel
	Tel	+32-3-369-1740
		Address record changed: 2024-01-05
Basic data	Employees	A: 1 to 10
		* Document for »About Section«: eTheRNA Immunotherapeutics N.V.. (2/3/22). "Press Release: eTheRNA Announces Research Agreement with Merck to Access mRNA technologies". Niel.
		Record changed: 2025-03-16

Advertisement

More documents for Etherna (Group)

• [1] Etherna N.V.. (7/10/24). "Press Release: Antonin (Tony) de Fougerolles Appointed as New Chair of Etherna". Niel....
• [2] Etherna N.V.. (4/16/24). "Press Release: Shelly West Joins Etherna as Business Development Director US". Niel....
• [3] Etherna N.V.. (10/17/23). "Press Release: mRNA/LNP Technology Platform Company Etherna Names Bernard Sagaert as Chief Executive Officer and Marijn Dekkers as Chairman of the Board". Niel....
• [4] Etherna N.V.. (6/8/23). "Press Release: Steffen Helmling Joins Etherna as Chief Business Officer". Niel....
• [5] eTheRNA Immunotherapeutics N.V.. (8/23/22). "Press Release: mRNA Leading Expert Kenneth Chien and Novalis LifeSciences’ Marijn Dekkers Investing EUR 39M Series B2 Financing in mRNA Technology Platform Company eTheRNA". Niel....
• [6] eTheRNA Immunotherapeutics N.V.. (2/3/22). "Press Release: eTheRNA Announces Research Agreement with Merck to Access mRNA technologies". Niel....
• [7] eTheRNA Immunotherapeutics N.V.. (8/3/21). "Press Release: eTheRNA Immunotherapies Opens Office in Hong Kong to Support and Build on Its Growing Activities in China and Broader Asia-Pacific". Niel....
• [8] eTheRNA Immunotherapeutics N.V.. (6/16/20). "Press Release: eTheRNA Raises EUR 34 Million in Series B Financing to Accelerate Multiple mRNA Therapeutic Development Programs Through to Clinical Proof of Concept". Niel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.